Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and answers are republished by permission. Q: I am in my 70s and have previously ...
5don MSN
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong phase 2 data
Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results